Literature DB >> 17322928

Mechanisms of disease: regulation of RANTES (CCL5) in renal disease.

Alan M Krensky1, Yong-Tae Ahn.   

Abstract

Chemokines (chemoattractant cytokines) are fundamental regulators of immune cell movement from the bloodstream into tissues. Regulating expression of chemokines might, therefore, alleviate inflammation in autoimmune diseases and transplant rejection, or augment immune responses in cancer and immunodeficiency. RANTES (regulated upon activation, normal T cell expressed and secreted [also known as CCL5]) is a model chemokine of relevance to a myriad of diseases. Regulation of RANTES expression is complex. In fibroblasts and monocytes, rel proteins alone suffice to induce transcription of RANTES. By contrast, expression of RANTES in T lymphocytes 3-5 days after activation requires the development of a molecular complex (enhancesome) including KLF13 (Krueppel-like factor 13), rel proteins p50 and p65, and scaffolding proteins. This complex recruits enzymes involved in acetylation, methylation and phosphorylation of chromatin, and ultimately in the expression of RANTES. In addition, KLF13-the lynchpin for recruitment of this molecular complex-is itself translationally regulated. Such complex regulation of biological systems has major implications for the rational design of drugs aimed at increasing or decreasing inflammatory responses in patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17322928      PMCID: PMC2702760          DOI: 10.1038/ncpneph0418

Source DB:  PubMed          Journal:  Nat Clin Pract Nephrol        ISSN: 1745-8323


  56 in total

1.  IL-4 inhibits the TNF-alpha induced proliferation of renal cell carcinoma (RCC) and cooperates with TNF-alpha to induce apoptotic and cytokine responses by RCC: implications for antitumor immune responses.

Authors:  Claudia Falkensammer; Karin Jöhrer; Hubert Gander; Reinhold Ramoner; Thomas Putz; Andrea Rahm; Richard Greil; Georg Bartsch; Martin Thurnher
Journal:  Cancer Immunol Immunother       Date:  2006-01-28       Impact factor: 6.968

2.  Overexpression of chemokines, fibrogenic cytokines, and myofibroblasts in human membranous nephropathy.

Authors:  S A Mezzano; M A Droguett; M E Burgos; L G Ardiles; C A Aros; I Caorsi; J Egido
Journal:  Kidney Int       Date:  2000-01       Impact factor: 10.612

3.  CC chemokines and chemokine receptors in IgA nephropathy (IgAN) and in non-IgA mesangial proliferative glomerulonephritis (MesProGN). the immunohistochemical comparative study.

Authors:  Małgorzata Wagrowska-Danilewicz; Marian Danilewicz; Olga Stasikowska
Journal:  Pol J Pathol       Date:  2005       Impact factor: 1.072

Review 4.  Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues.

Authors:  Lisa M Ebert; Patrick Schaerli; Bernhard Moser
Journal:  Mol Immunol       Date:  2004-11-23       Impact factor: 4.407

5.  Chemokine expression in the obstructed kidney.

Authors:  J M Crisman; L L Richards; D P Valach; D F Franzoni; J R Diamond
Journal:  Exp Nephrol       Date:  2001

6.  Expression of chemokines and their receptors in nephrotoxic serum nephritis.

Authors:  E Schadde; M Kretzler; B Banas; B Luckow; K Assmann; D Schlöndorff
Journal:  Nephrol Dial Transplant       Date:  2000-07       Impact factor: 5.992

7.  CC chemokine ligand 5/RANTES chemokine antagonists aggravate glomerulonephritis despite reduction of glomerular leukocyte infiltration.

Authors:  Hans-Joachim Anders; Michael Frink; Yvonne Linde; Bernard Banas; Markus Wörnle; Clemens D Cohen; Volker Vielhauer; Peter J Nelson; Hermann-Josef Gröne; Detlef Schlöndorff
Journal:  J Immunol       Date:  2003-06-01       Impact factor: 5.422

8.  Interleukin-1beta induction of the chemokine RANTES promoter in the human astrocytoma line CH235 requires both constitutive and inducible transcription factors.

Authors:  N G Miyamoto; P S Medberry; J Hesselgesser; S Boehlk; P J Nelson; A M Krensky; H D Perez
Journal:  J Neuroimmunol       Date:  2000-06-01       Impact factor: 3.478

9.  Stimulus specificity of matrix metalloproteinase dependence of human T cell migration through a model basement membrane.

Authors:  M Xia; D Leppert; S L Hauser; S P Sreedharan; P J Nelson; A M Krensky; E J Goetzl
Journal:  J Immunol       Date:  1996-01-01       Impact factor: 5.422

10.  Differential expression of beta-chemokines MCP-1 and RANTES and their receptors CCR1, CCR2, CCR5 in acute rejection and chronic allograft nephropathy of human renal allografts.

Authors:  M Rüster; H Sperschneider; R Fünfstück; G Stein; H J Gröne
Journal:  Clin Nephrol       Date:  2004-01       Impact factor: 0.975

View more
  59 in total

1.  Rantes/Ccl5 influences hematopoietic stem cell subtypes and causes myeloid skewing.

Authors:  Aysegul V Ergen; Nathan C Boles; Margaret A Goodell
Journal:  Blood       Date:  2012-01-30       Impact factor: 22.113

2.  Inhibition of proinflammatory RANTES expression by TGF-beta1 is mediated by glycogen synthase kinase-3beta-dependent beta-catenin signaling.

Authors:  Chunsun Dai; Xiaoyan Wen; Weichun He; Youhua Liu
Journal:  J Biol Chem       Date:  2010-12-28       Impact factor: 5.157

3.  Resistant starch supplementation attenuates inflammation in hemodialysis patients: a pilot study.

Authors:  Bruna Regis de Paiva; Marta Esgalhado; Natália Alvarenga Borges; Julie Ann Kemp; Gutemberg Alves; Paulo Emílio Corrêa Leite; Renata Macedo; Ludmila F M F Cardozo; Jessyca Sousa de Brito; Denise Mafra
Journal:  Int Urol Nephrol       Date:  2020-02-01       Impact factor: 2.370

4.  Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity.

Authors:  Sherine F Elsawa; Anne J Novak; Steven C Ziesmer; Luciana L Almada; Lucy S Hodge; Deanna M Grote; Thomas E Witzig; Martin E Fernandez-Zapico; Stephen M Ansell
Journal:  Blood       Date:  2011-09-14       Impact factor: 22.113

Review 5.  New insights into epithelial-mesenchymal transition in kidney fibrosis.

Authors:  Youhua Liu
Journal:  J Am Soc Nephrol       Date:  2009-12-17       Impact factor: 10.121

6.  The Fli-1 transcription factor regulates the expression of CCL5/RANTES.

Authors:  Mara L Lennard Richard; Shuzo Sato; Eiji Suzuki; Sarah Williams; Tamara K Nowling; Xian K Zhang
Journal:  J Immunol       Date:  2014-08-06       Impact factor: 5.422

7.  Intravenous tolerance modulates macrophage classical activation and antigen presentation in experimental autoimmune encephalomyelitis.

Authors:  Hongmei Li; Bogoljub Ciric; Jingxian Yang; Hui Xu; Denise C Fitzgerald; Mohamed Elbehi; Zoe Fonseca-Kelly; Shuo Yu; Guang-Xian Zhang; Abdolmohamad Rostami
Journal:  J Neuroimmunol       Date:  2009-02-01       Impact factor: 3.478

8.  Microfluidic mazes to characterize T-cell exploration patterns following activation in vitro.

Authors:  Namrata G Jain; Elisabeth A Wong; Alexander J Aranyosi; Leo Boneschansker; James F Markmann; David M Briscoe; Daniel Irimia
Journal:  Integr Biol (Camb)       Date:  2015-11       Impact factor: 2.192

9.  De novo expression of circulating biglycan evokes an innate inflammatory tissue response via MyD88/TRIF pathways.

Authors:  Jinyang Zeng-Brouwers; Janet Beckmann; Madalina-Viviana Nastase; Renato V Iozzo; Liliana Schaefer
Journal:  Matrix Biol       Date:  2013-12-18       Impact factor: 11.583

10.  Decreased expression of miR-125b and miR-100 in oral cancer cells contributes to malignancy.

Authors:  Brian J Henson; Samsiddhi Bhattacharjee; Dawn M O'Dee; Eleanor Feingold; Susanne M Gollin
Journal:  Genes Chromosomes Cancer       Date:  2009-07       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.